Summit Therapeutics Inc. Weighted Average Remaining Contractual Life Of Outstanding Share Options
Summit Therapeutics Inc. (SMMT) had Weighted Average Remaining Contractual Life Of Outstanding Share Options of 9.2 year as of 2019-01-31, per its 20-F filed 2019-03-29.
Discontinued › Notes
ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions · last filed 2019-03-29
- 2019-01-31: Weighted Average Remaining Contractual Life Of Outstanding Share Options 9.20 year.
- 2018-01-31: Weighted Average Remaining Contractual Life Of Outstanding Share Options 7.90 year.
- 2017-01-31: Weighted Average Remaining Contractual Life Of Outstanding Share Options 8.90 year.
| Period end | Weighted Average Remaining Contractual Life Of Outstanding Share Options |
|---|---|
| 2019-01-31 | 9.20 year 20-F · filed 2019-03-29 |
| 2018-01-31 | 7.90 year 20-F · filed 2019-03-29 |
| 2017-01-31 | 8.90 year 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |